Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Pancreatic Cancer
Both
Pancreatic Cancer
Trial Information
Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Inclusion Criteria:
1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and
2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.
Exclusion criteria:
1) are absolute contraindications to intravenous iodinated contrast or CT scan.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Histological markers of tumor angiogenesis (microvessel density, EGF/VEGF expression level)
Outcome Time Frame:
1 day
Safety Issue:
No
Principal Investigator
Aya Kamaya
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
PANC0009
NCT ID:
NCT01326364
Start Date:
March 2010
Completion Date:
September 2015
Related Keywords:
- Pancreatic Cancer
- Pancreatic Neoplasms
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
